文献速递妇科产科

Lifastuzumab vedotin联合卡铂治疗铂敏感复发性卵巢癌的1b期研究

Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2020-06-11

这项开放标签、多中心1b期研究评估了抗体药物偶联物LIFA联合卡铂(±贝伐珠单抗)在铂敏感复发性卵巢癌患者中的安全性和耐受性。LIFA每3周静脉给药,起始剂量1.2 mg/kg,采用3+3剂量递增,卡铂AUC6每3周用6周期。未达到最大耐受剂量,推荐2期剂量为LIFA 2.4 mg/kg联合卡铂AUC6(±贝伐珠单抗15 mg/kg)。所有患者发生不良事件,83%发生≥3级不良事件,最常见为中性粒细胞减少和血小板减少;24例(59%)确认完全或部分缓解,中位无进展生存期10.71个月(95%CI: 8.54, 13.86)。

要点

  • 推荐2期剂量为LIFA 2.4 mg/kg联合卡铂AUC6(±贝伐珠单抗15 mg/kg)。
  • 83%患者发生≥3级不良事件,最常见为中性粒细胞减少和血小板减少。
  • 24例(59%)确认完全或部分缓解,中位无进展生存期10.71个月。

核心结论

  • LIFA联合卡铂(±贝伐珠单抗)在铂敏感复发性卵巢癌患者中显示出可接受的安全性和令人鼓舞的抗肿瘤活性。

研究设计与样本

  • 开放标签、多中心1b期研究,LIFA每3周静脉给药,起始剂量1.2 mg/kg,采用3+3剂量递增。
  • 所有患者接受卡铂AUC6每3周,最多6周期。
  • 剂量扩展队列接受±贝伐珠单抗15 mg/kg每3周。

主要发现

  • 未达到最大耐受剂量。
  • 所有患者发生至少1次不良事件;34例(83%)发生≥3级不良事件,最常见为中性粒细胞减少和血小板减少。
  • 9例(22%)发生严重不良事件;肺毒性发生率34%,1例因2级肺炎停止研究治疗。
  • 24例(59%)确认完全或部分缓解;中位无进展生存期10.71个月(95%CI: 8.54, 13.86)。
  • 单药LIFA的药代动力学与联合治疗相似。

关键数值与推荐

  • 推荐2期剂量为LIFA 2.4 mg/kg联合卡铂AUC6(周期1-6),联合或不联合贝伐珠单抗15 mg/kg。
  • 最常见治疗相关不良事件包括中性粒细胞减少、周围神经病、血小板减少、恶心、乏力、贫血、腹泻、呕吐、低镁血症、天冬氨酸氨基转移酶升高、丙氨酸氨基转移酶升高和脱发。

临床怎么用

  • 对于铂敏感复发性卵巢癌患者,可考虑LIFA 2.4 mg/kg联合卡铂AUC6(±贝伐珠单抗15 mg/kg)每3周方案。
  • 治疗期间需重点监测中性粒细胞减少、血小板减少和周围神经病等不良事件,并警惕肺毒性。

局限性

  • 本研究为1b期单臂研究,样本量有限,未设对照组,疗效需进一步随机对照试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study investigated the safety and tolerability of lifastuzumab vedotin (DNIB0600A) (LIFA), an antibody-drug conjugate, in patients with recurrent platinum-sensitive ovarian cancer (PSOC). METHODS: In this open-label, multicenter phase 1b study, LIFA was administered intravenously once every 3 weeks (Q3W) with starting dose 1.2 mg/kg in a 3 + 3 dose-escalation scheme. All patients received carboplatin at dose AUC 6 mg/mL·min (AUC6) Q3W for up to 6 cycles. Dose expansion cohorts were enrolled ± bevacizumab 15 mg/kg Q3W. RESULTS: Patients received LIFA at 1.2, 1.8, and 2.4 mg (n = 4, 5, and 20, respectively) with carboplatin. The maximum tolerated dose was not reached. The recommended phase 2 dose (RP2D) was LIFA 2.4 mg/kg + carboplatin AUC6 (cycles 1-6), with or without bevacizumab 15 mg/kg. Twelve patients received RP2D with bevacizumab. All patients experienced ≥1 adverse event (AE). The most common treatment-related AEs were neutropenia, peripheral neuropathy, thrombocytopenia, nausea, fatigue, anemia, diarrhea, vomiting, hypomagnesaemia, aspartate aminotransferase increased, alanine aminotransferase increased, and alopecia. Thirty-four (83%) patients experienced grade ≥ 3 AEs, the most frequent of which were neutropenia and thrombocytopenia. Nine (22%) patients experienced serious AEs. Pulmonary toxicities (34%), considered a potential risk of LIFA, included one patient who discontinued study treatment due to grade 2 pneumonitis. The median duration of progression-free survival was 10.71 months (95% CI: 8.54, 13.86) with confirmed complete/partial responses in 24 (59%) patients. Pharmacokinetics of mono-therapy LIFA was similar in combination therapy. CONCLUSION: LIFA in combination with carboplatin ± bevacizumab demonstrated acceptable safety and encouraging activity in PSOC patients.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Moore KN, Birrer MJ, Marsters J, et al. Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer. Gynecol Oncol. 2020. PMID: 32534811. doi:10.1016/j.ygyno.2020.05.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。